ERBB2 and breast carcinoma: LPB (Fig. 1) is a significant promising drug molecules, approved by FDA, USA is being utilizing for the development of a nontoxic and effective targeted therapy against breast cancer.7 The LPB clinical effectiveness in combination with capecitabine has exhibited efficacy contrary to HER2-positive breast cancer.8 Besides, LPB-loaded human serum albumin nano particles have been proposed as a nontoxic therapy against HER2-positive cells.9 LPB belongs to a class of tyrosine kinase inhibitor, is hydrophobic in nature.